We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 ("RETRIEVE 3") (RETRIEVE 3)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 11, 2010
Last Update Posted: June 30, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Crux Biomedical
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.

Condition Intervention Phase
Pulmonary Embolism Device: Inferior Vena Cava Filter Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3

Resource links provided by NLM:

Further study details as provided by Crux Biomedical:

Primary Outcome Measures:
  • Clinical Success [ Time Frame: 6 Months ]
    Clinical Success is a composite endpoint consisting of technical success with freedom from pulmonary embolism, filter migration and device related events requiring intervention.

Secondary Outcome Measures:
  • Retrieval Success [ Time Frame: 6 months ]
  • Filter Migration [ Time Frame: 6 Months ]
  • VCF Thrombus [ Time Frame: 6 Months ]
  • Device Integrity [ Time Frame: 6 Months ]

Enrollment: 17
Study Start Date: May 2010
Study Completion Date: January 2012
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Crux Vena Cava Filter System
Subjects at risk for Pulmonary Embolism
Device: Inferior Vena Cava Filter
Inplant of filter in inferior vena cava.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has a permanent or temporary risk of Pulmonary Embolism.
  • Patient must provide informed consent At least one of the following conditions -
  • Proven PE
  • Recurrent PE despite adequate
  • Contraindication to anticoagulation
  • Inability to achieve/maintain therapeutic anticoagulation
  • Iliocaval DVT
  • Large, free-floating proximal DVT
  • Massive PE treated with thrombolysis/thrombectomy
  • Chronic PE treated with thrombectomy
  • Protection during thrombolysis for iliocaval DVT
  • PE with limited cardiopulmonary reserve
  • Poor compliance with anticoagulation medication
  • High risk of injury worsening on anticoagulation
  • Multi-trauma patient with high risk of PE
  • Surgical patients at high risk of PE
  • Medical condition with high risk of PE Patients with a documented vena cava diameter of 17-28mm Patient has IVC anatomy suitable for infra-renal placement Patient is willing to be available for the appropriate follow up

Exclusion Criteria:

  • Age <18 years old
  • Patient has any one of the following conditions:

    • Renal vein thrombosis
    • IVC thrombosis extending to the renal veins
    • Duplicate IVC
    • Gonadal vein thrombosis
    • Requires supra-renal placement
  • Vena cava diameter of 17-28mm
  • Uncontrolled infectious disease
  • Risk of aseptic PE
  • Uncontrolled coagulopathy
  • Existing inferior vena cava filter implant
  • Life expectancy less than 6 months
  • Pregnant or planning a pregnancy in the next 6 months
  • Condition that inhibits radiographic visualization of the IVC
  • Known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol
  • Known hypersensitivity to contract which cannot be pretreated
  • Access vessels preclude same insertion of delivery system
  • Participation in another drug or device trial
  • Unable or unwilling to cooperate with study procedures or required follow-up visits
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01120522

Imelda Hospital
Bonheiden, Belgium
A. Z. St. Blasius Hospital
Dendermonde, Belgium
Sponsors and Collaborators
Crux Biomedical
  More Information

Additional Information:
Responsible Party: Crux Biomedical
ClinicalTrials.gov Identifier: NCT01120522     History of Changes
Other Study ID Numbers: Crux03
First Submitted: May 6, 2010
First Posted: May 11, 2010
Last Update Posted: June 30, 2014
Last Verified: February 2012

Keywords provided by Crux Biomedical:
Vena Cava
Vena Cava Filter
Pulmonary Embolism
Venous Thromboembolism
Risk of Pulmonary Embolism

Additional relevant MeSH terms:
Pulmonary Embolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases